Research interests
CardioTTRansform-OLE awarded by Ionis Pharmaceuticals Inc, 2023 to 2028[9]
2023 to 2028
Fawaz Alenezi
Cardiac MRI Fellowship at Duke University, 2018 to 2020
As of 2020 · Last known relationship
Cardiac MRI Fellowship at Duke University, 2018 to 2020
As of 2020 · Last known relationship
Fawaz Alenezi is an Associate Professor of Medicine at Duke University whose work combines cardiovascular imaging with clinical research. His documented research includes artificial intelligence applied to echocardiography to identify and characterize pulmonary hypertension and hypertrophic cardiomyopathy, as well as studies of cardiac function and immune status in people living with HIV. He was first author and presenting investigator for two AI echocardiography studies presented at the 2026 European Society of Cardiology Congress. His training includes an M.D. from Dnipropetrovsk State Medical Academy, internal medicine and cardiology training at Cairo University Hospital, and Duke fellowships in echocardiography, cardiac CT, and cardiac MRI. He also presented a 2017 Cardiovascular Imaging Grand Rounds session on strain echocardiography.
Each topic is linked to its supporting source in Sources.
Training includes Cardiac MRI Fellowship at Duke University, 2018 to 2020, Cardiac CT Fellowship at Duke University, 2017 to 2018, Presented Cardiovascular Imaging Grand Rounds, “CDU: Your Guide for Supraventricular Strain Echocardiography,” on January 12, 2017, and Echocardiography Fellowship at Duke University, 2013 to 2017, plus 10 more records.
Explore education and trainingAs of 2020
As of 2018
As of 2017
As of 2017
As of 2016
As of 2005
CardioTTRansform-OLE awarded by Ionis Pharmaceuticals Inc, 2023 to 2028[9]
2023 to 2028
First author and presenting investigator for two AI echocardiography studies at the 2026 European Society of Cardiology Congress[12]
2026
Publication: “Cardiovascular Outcomes with Colchicine in Coronary Artery Disease and HFpEF: A Propensity-Matched TriNetX Analysis,” 2026[9]
2026
Publication: “Clinical and electrical outcomes of conduction system pacing versus right ventricular pacing in atrioventricular block: a systematic review and meta-analysis,” 2026[9]
2026
Publication: “Clinical Outcomes of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Heart Failure: A Real-World Propensity-Matched TriNetX Analysis,” 2026[9]
2026
Publication: “Clinical outcomes with vutrisiran in transthyretin amyloidosis: a systematic review and meta-analysis of randomized trials,” 2026[9]
2026
Publication: “Comparative Effectiveness of Finerenone Versus SGLT2 Inhibitors in Patients with HFpEF and CKD: A Real-World Propensity-Matched TriNetX Analysis,” 2026[9]
2026
Publication: “Comparative outcomes of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and liver cirrhosis: A propensity score matched TriNetX analysis,” 2026[9]
2026
Publication: “Comparative Outcomes of Transcatheter Versus Surgical Pulmonary Valve Replacement in Adults With Congenital Heart Disease,” 2026[9]
2026
Publication: “Early Rhythm Versus Rate Control in Older Adults With New-Onset Atrial Fibrillation: A Propensity Score-Matched Analysis,” 2026[9]
2026
Publication: “Fatal Cardiogenic Shock in Patients with Heart Failure: National Mortality Trends, Forecasting, and the Influence of Atherosclerotic Cardiovascular Disease in the United States in 1999–2023,” 2026[9]
2026
Publication: “Global longitudinal strain and immune status in patients living with human immunodeficiency virus,” 2019[10]
2019
Publication: “Intracardiac vs. Transesophageal echocardiography in left atrial appendage occlusion: real-world comparative effectiveness from a propensity-matched cohort,” 2026[9]
2026
Pulmonary Structure and Function with Hyperpolarized 129Xe Magnetic Resonance Imaging in Patients with Pulmonary Hypertension, awarded by the American Heart Association, 2023 to 2026[9]
2023 to 2026
Research on the relationship between immune status and left ventricular function in people with HIV[10]
Research using AI with echocardiography to identify and characterize pulmonary hypertension and hypertrophic cardiomyopathy[12]
2026